Tritonix.ai

News / Taiwan / economic_daily

Oasmia Pharmaceutical Shares Surge to Limit Up as Market Plunges Amid Novartis ADC Deal

Health Technology · Biotechnology · economic_daily · 2026-11-16

4174, 8463

Despite a massive 2,600-point drop in the Taiwan stock market, Oasmia Pharmaceutical shares hit the daily limit after announcing a major ADC platform licensing deal with Novartis.

What Happened

Market Sell-off: The Taiwan stock market faced a severe downturn on the 16th, plummeting over 2,600 points to close at 41,040.08, driven by political and business tensions surrounding the resignation of NVIDIA's former CEO.

Oasmia's Resilience: Defying the broader market crash, Oasmia Pharmaceutical shares defied the trend and hit the daily limit, closing at 71.3 TWD, marking a two-year high. The stock's performance was fueled by positive news regarding a strategic international partnership.

ADC Platform Partnership: Oasmia has entered into a licensing agreement with Novartis to utilize its proprietary Antibody-Drug Conjugate (ADC) platform. The collaboration aims to develop next-generation cancer therapies by combining Oasmia's technology with Novartis's novel drug payloads.

Financial Upside: The deal includes an upfront payment of $30 million, with total potential milestone payments exceeding $2 billion based on development and commercialization progress. Oasmia also retains the right to receive royalties on net sales of products resulting from the collaboration.

Read original

More in Health Technology

Latest in Taiwan